AA
TXMD icon

ALPS Advisors’s TherapeuticsMD TXMD Stock Holding History

ALPS Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,382
Closed -$1.22M – 786
2017
Q1 		$1.22M Sell
3,382
-396
-10% -$123K 0.01% 202
2016
Q4 		$1.09M Sell
3,778
-1,232
-25% -$382K 0.01% 214
2016
Q3 		$1.71M Sell
5,010
-504
-9% -$184K 0.01% 194
2016
Q2 		$2.34M Buy
+5,514
New +$2.27M 0.02% 160

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

ALPS Advisors's TXMD Position: Q2 2017 in Review

ALPS Advisors sold out of TherapeuticsMD (TXMD) in Q2 2017, closing a stake of 3,382 shares — an estimated $1.22M sold.

ALPS Advisors first reported a position in TXMD in Q2 2016 and held it in 4 quarters. The position peaked at $2.34M in Q2 2016. 117 funds tracked by Wall St. Rank hold TXMD as of Q2 2017.

  • ALPS Advisors reported no remaining TherapeuticsMD position as of Q2 2017 after selling out during the quarter.
  • ALPS Advisors sold 3,382 TherapeuticsMD shares in Q2 2017, an estimated $1.22M.
  • ALPS Advisors first reported a position in TherapeuticsMD in Q2 2016 and held it in 4 quarters.
  • ALPS Advisors's TherapeuticsMD position peaked at $2.34M in Q2 2016.
  • 117 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2017.

Based on ALPS Advisors's 13F filing for Q2 2017, filed 3 Aug 2017.